Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells
暂无分享,去创建一个
Henriqueta Louro | M. J. Silva | H. Louro | M. Boavida | Marco Valente | Maria J Silva | Paula Costa | Anabela Dias | Maria G Boavida | M. Valente | A. Dias | P. Costa | Paula Costa | M. Silva
[1] Eric D. Scheeff,et al. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. , 1999, Molecular pharmacology.
[2] B. Glickman,et al. Sequence specificity of mutation induced by the anti-tumor drug cisplatin in the CHO aprt gene. , 1989, Carcinogenesis.
[3] M. J. Pillaire,et al. Mutagenesis in monkey cells of a vector containing a single d(GPG) cis- diamminedichloroplatinum(II) adduct placed on codon 13 of the human H- ras proto-oncogene , 1994, Nucleic Acids Res..
[4] E. Raymond,et al. Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.
[5] P. Lohman,et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.
[6] S. Lippard,et al. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). , 1995, Nucleic acids research.
[7] T. Kunkel,et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.
[8] E. Cvitkovic. Ongoing and unsaid on oxaliplatin: the hope. , 1998, British Journal of Cancer.
[9] C. Napier,et al. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. , 1998, Molecular pharmacology.
[10] M. Giphart-Gassler,et al. Heterozygous Aprt mouse model: Detection and study of a broad range of autosomal somatic mutations in vivo , 1999, Environmental and molecular mutagenesis.
[11] S. Aebi,et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. , 1997, Cancer research.
[12] R. Fuchs,et al. Single d(ApG)/cis-diamminedichloroplatinum(II) adduct-induced mutagenesis in Escherichia coli. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Aardema,et al. Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. , 1999, Mutation research.
[14] R. Rietbroek,et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.
[15] B. A. Kunz,et al. Analysis of mutations induced in the SUP4-o gene of Saccharomyces cerevisiae by cis-diammine dichloroplatinum(II). , 1990, Carcinogenesis.
[16] H. Bleiberg. Oxaliplatin (L-OHP): a new reality in colorectal cancer. , 1998, British Journal of Cancer.
[17] M. Pillaire,et al. In Vitro Bypass Replication of the Cisplatin-d(GpG) Lesion by Calf Thymus DNA Polymerase β and Human Immunodeficiency Virus Type I Reverse Transcriptase Is Highly Mutagenic* , 1996, The Journal of Biological Chemistry.
[18] C. R. Valentine,et al. Genomic DNA sequencing of mRNA splicing mutants in the hprt gene of chinese hamster ovary cells , 1995, Environmental and molecular mutagenesis.
[19] I. M. Jones,et al. Mapping the end points of large deletions affecting the hprt locus in human peripheral blood cells and cell lines. , 1995, Radiation research.
[20] S. Chaney,et al. The Role of DNA Polymerase η in Translesion Synthesis Past Platinum–DNA Adducts in Human Fibroblasts , 2004, Cancer Research.
[21] D. Muzny,et al. The Chinese hamster HPRT gene: restriction map, sequence analysis, and multiplex PCR deletion screen. , 1991, Genomics.
[22] J. Thacker,et al. Formation of large deletions by illegitimate recombination in the HPRT gene of primary human fibroblasts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Schwartz,et al. Dose-Dependent Changes in the Spectrum of Mutations Induced by Ionizing Radiation , 2000, Radiation research.
[24] C. McCall,et al. Frameshifts and deletions during in vitro translesion synthesis past Pt–DNA adducts by DNA polymerases β and η , 2002 .
[25] R. Fuchs,et al. Spectrum of cisplatin-induced mutations in Escherichia coli. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Marinus,et al. MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.
[27] I. Roninson,et al. Identification of p53 genetic suppressor elements which confer resistance to cisplatin , 1997, Oncogene.
[28] J. Essigmann,et al. Mechanisms of resistance to cisplatin. , 2001, Mutation research.
[29] W. T. Adams,et al. Computer program for the analysis of mutational spectra: application to p53 mutations. , 1994, Carcinogenesis.
[30] M. Marinus,et al. Multiple pathways of recombination define cellular responses to cisplatin. , 2000, Chemistry & biology.
[31] J. Miller,et al. Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. , 1981, Cancer research.
[32] S. Ehrlich,et al. RuvAB Acts at Arrested Replication Forks , 1998, Cell.
[33] J. C. Jones,et al. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. , 1991, The Journal of biological chemistry.
[34] E. Raymond,et al. Oxaliplatin-induced damage of cellular DNA. , 2000, Molecular pharmacology.
[35] M. J. Silva,et al. Mutagenic activity of cisplatin in the lacZ plasmid‐based transgenic mouse model , 2002, Environmental and molecular mutagenesis.
[36] P. van de Putte,et al. Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II). , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[37] E. Raymond,et al. Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] T. Skopek,et al. In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene. , 1992, Cancer research.
[39] P. Hall,et al. Treatment-associated leukemia following testicular cancer. , 2000, Journal of the National Cancer Institute.
[40] K. Paull,et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.
[41] C. Macleod,et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.
[42] F. Zunino,et al. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. , 2003, Current cancer drug targets.
[43] S. Lippard,et al. Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). , 1993, Biochemistry.
[44] M. Meltz,et al. Molecular nature of spontaneous mutations at the hypoxanthine‐guanine phosphoribosyltransferase (hprt) locus in chinese hamster ovary cells , 1995, Environmental and molecular mutagenesis.
[45] M. Meuth,et al. Deletion mapping of highly conserved transcribed sequence downstream fromAPRT locus , 1995, Somatic cell and molecular genetics.
[46] E. Raymond,et al. Activity of oxaliplatin against human tumor colony-forming units. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] D. Jenssen,et al. Spectrum of spontaneously occurring mutations in the hprt gene of V79 Chinese hamster cells. , 1992, Journal of molecular biology.
[48] F. Hanaoka,et al. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. , 2000, Biochemistry.
[49] N. Berinstein,et al. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity , 1998, Oncogene.
[50] J. Ward,et al. Transplacental carcinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. , 1995, Toxicology and Applied Pharmacology.
[51] J. Wang,et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.
[52] P. Karran,et al. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. , 1997, Nucleic acids research.
[53] S. Chaney. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). , 1995, International journal of oncology.
[54] P. Jordan,et al. Molecular mechanisms involved in cisplatin cytotoxicity , 2000, Cellular and Molecular Life Sciences CMLS.
[55] A. E. Kilburn,et al. Recombination-dependent deletion formation in mammalian cells deficient in the nucleotide excision repair gene ERCC1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[56] P. O'Connor,et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines , 1992, Molecular and cellular biology.
[57] S. Faivre,et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. , 2003, Biochemical pharmacology.
[58] Adams Wt,et al. Statistical test for the comparison of samples from mutational spectra , 1987 .